CL2007003583A1 - Formulacion farmaceutica estable, parenteral, del anticuerpo contra el peptido beta amiloide (abeta); y uso de la formulacion para el tratamiento de la enfermedad de alzheimer. - Google Patents
Formulacion farmaceutica estable, parenteral, del anticuerpo contra el peptido beta amiloide (abeta); y uso de la formulacion para el tratamiento de la enfermedad de alzheimer.Info
- Publication number
- CL2007003583A1 CL2007003583A1 CL200703583A CL2007003583A CL2007003583A1 CL 2007003583 A1 CL2007003583 A1 CL 2007003583A1 CL 200703583 A CL200703583 A CL 200703583A CL 2007003583 A CL2007003583 A CL 2007003583A CL 2007003583 A1 CL2007003583 A1 CL 2007003583A1
- Authority
- CL
- Chile
- Prior art keywords
- formulation
- abeta
- alzheimer
- disease
- stable
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Neurology (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP06025590 | 2006-12-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2007003583A1 true CL2007003583A1 (es) | 2008-07-18 |
Family
ID=39190366
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL200703583A CL2007003583A1 (es) | 2006-12-11 | 2007-12-11 | Formulacion farmaceutica estable, parenteral, del anticuerpo contra el peptido beta amiloide (abeta); y uso de la formulacion para el tratamiento de la enfermedad de alzheimer. |
Country Status (21)
Country | Link |
---|---|
US (1) | US20110070225A1 (es) |
EP (1) | EP2094729A1 (es) |
JP (1) | JP2010512356A (es) |
KR (1) | KR20090104017A (es) |
CN (1) | CN101553504A (es) |
AR (1) | AR064220A1 (es) |
AU (1) | AU2007331712A1 (es) |
BR (1) | BRPI0721097A2 (es) |
CA (1) | CA2671968A1 (es) |
CL (1) | CL2007003583A1 (es) |
CR (1) | CR10823A (es) |
EC (1) | ECSP099403A (es) |
IL (1) | IL198963A0 (es) |
MA (1) | MA30975B1 (es) |
MX (1) | MX2009006199A (es) |
NO (1) | NO20092586L (es) |
PE (1) | PE20081477A1 (es) |
RU (1) | RU2009126420A (es) |
TW (1) | TW200831133A (es) |
WO (1) | WO2008071394A1 (es) |
ZA (1) | ZA200904014B (es) |
Families Citing this family (70)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20160279239A1 (en) | 2011-05-02 | 2016-09-29 | Immunomedics, Inc. | Subcutaneous administration of anti-cd74 antibody for systemic lupus erythematosus and autoimmune disease |
DE10303974A1 (de) | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung |
TW200530269A (en) | 2003-12-12 | 2005-09-16 | Chugai Pharmaceutical Co Ltd | Anti-Mpl antibodies |
US20160355591A1 (en) | 2011-05-02 | 2016-12-08 | Immunomedics, Inc. | Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies |
US9493569B2 (en) | 2005-03-31 | 2016-11-15 | Chugai Seiyaku Kabushiki Kaisha | Structural isomers of sc(Fv)2 |
CN101262885B (zh) | 2005-06-10 | 2015-04-01 | 中外制药株式会社 | 含有sc(Fv)2的药物组合物 |
CN101432302A (zh) | 2005-11-30 | 2009-05-13 | 艾博特公司 | 抗-Aβ球聚体抗体,其抗原结合部分,相应的杂交瘤、核酸、载体、宿主细胞,生产所述抗体的方法,包含所述抗体的组合物,所述抗体的应用以及使用所述抗体的方法 |
CA2631195C (en) | 2005-11-30 | 2016-04-05 | Abbott Laboratories | Monoclonal antibodies against amyloid beta protein and uses thereof |
PT1960428E (pt) * | 2005-12-12 | 2011-10-07 | Hoffmann La Roche | Anticorpos glicosilados na região variável contra beta-amilóide 4 |
US8455626B2 (en) | 2006-11-30 | 2013-06-04 | Abbott Laboratories | Aβ conformer selective anti-aβ globulomer monoclonal antibodies |
EP2124952A2 (en) | 2007-02-27 | 2009-12-02 | Abbott GmbH & Co. KG | Method for the treatment of amyloidoses |
US8613923B2 (en) | 2007-06-12 | 2013-12-24 | Ac Immune S.A. | Monoclonal antibody |
US8048420B2 (en) | 2007-06-12 | 2011-11-01 | Ac Immune S.A. | Monoclonal antibody |
CA2701793C (en) | 2007-10-05 | 2017-04-25 | Genentech, Inc. | Use of anti-amyloid beta antibody in ocular diseases |
CN101970493A (zh) | 2008-03-14 | 2011-02-09 | 百康有限公司 | 单克隆抗体及其方法 |
AU2009259901B2 (en) * | 2008-06-20 | 2016-02-04 | Massachusetts Institute Of Technology | Immunoglobulins with reduced aggregation |
SG2014011365A (en) * | 2008-09-19 | 2014-05-29 | Hoffmann La Roche | Novel antibody formulation |
CN104740631B (zh) * | 2008-10-29 | 2019-04-16 | 阿布林克斯公司 | 单域抗原结合性分子的制剂 |
EP2346900A1 (en) | 2008-10-29 | 2011-07-27 | Wyeth LLC | Methods for purification of single domain antigen binding molecules |
PE20120169A1 (es) * | 2008-11-17 | 2012-02-29 | Genentech Inc | Metodo y formulacion para reducir la agregacion de una macromolecula bajo condiciones fisiologicas |
EP2196476A1 (en) * | 2008-12-10 | 2010-06-16 | Novartis Ag | Antibody formulation |
WO2010069858A1 (en) * | 2008-12-19 | 2010-06-24 | F. Hoffmann-La Roche Ag | Pharmaceutical composition |
WO2010100179A2 (en) * | 2009-03-05 | 2010-09-10 | Novartis Ag | Self-forming gel system for sustained drug delivery |
AU2010320515B2 (en) * | 2009-11-20 | 2013-05-02 | Biocon Limited | Formulations of antibody |
WO2011080209A2 (en) * | 2009-12-29 | 2011-07-07 | F. Hoffmann-La Roche Ag | Novel antibody formulation |
AR080428A1 (es) | 2010-01-20 | 2012-04-11 | Chugai Pharmaceutical Co Ltd | Formulaciones liquidas estabilizadas contentivas de anticuerpos |
MX2012009755A (es) | 2010-02-26 | 2012-09-12 | Novo Nordisk As | Composiciones que contienen anticuerpo estable. |
BR112012022258A2 (pt) | 2010-03-01 | 2016-10-25 | Bayer Healthcare Llc | anticorpos monoclonais otimizados contra inibidor de trajetória de fator de tecido ( tfpi) |
TW201144437A (en) | 2010-03-03 | 2011-12-16 | Boehringer Ingelheim Int | A-beta binding polypeptides |
US8987419B2 (en) | 2010-04-15 | 2015-03-24 | AbbVie Deutschland GmbH & Co. KG | Amyloid-beta binding proteins |
WO2011147921A1 (en) | 2010-05-28 | 2011-12-01 | Novo Nordisk A/S | Stable multi-dose compositions comprising an antibody and a preservative |
SG187173A1 (en) | 2010-07-30 | 2013-02-28 | Ac Immune Sa | Safe and functional humanized anti beta-amyloid antibody |
MX358739B (es) | 2010-08-14 | 2018-09-03 | Abbvie Inc Star | Proteinas de union a amiloide beta. |
WO2012028683A1 (en) * | 2010-09-02 | 2012-03-08 | Novartis Ag | Antibody gel system for sustained drug delivery |
WO2012151247A2 (en) * | 2011-05-02 | 2012-11-08 | Millennium Pharmaceuticals, Inc. | FORMULATION FOR ANTI-α4β7 ANTIBODY |
CA2831572C (en) | 2011-05-02 | 2019-11-26 | Immunomedics, Inc. | Ultrafiltration concentration of allotype selected antibodies for small-volume administration |
UA116189C2 (uk) | 2011-05-02 | 2018-02-26 | Мілленніум Фармасьютікалз, Інк. | КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА |
CN104023743B (zh) * | 2011-10-25 | 2017-05-03 | 普罗西纳治疗有限公司 | 抗体制剂和方法 |
HUE028440T2 (en) * | 2012-03-08 | 2016-12-28 | Hoffmann La Roche | Abeta antibody preparation |
US9592289B2 (en) | 2012-03-26 | 2017-03-14 | Sanofi | Stable IgG4 based binding agent formulations |
RU2644214C2 (ru) * | 2012-03-26 | 2018-02-08 | Санофи | СТАБИЛЬНЫЕ ПРЕПАРАТЫ СВЯЗЫВАЮЩЕГО СРЕДСТВА НА ОСНОВЕ IgG4 |
US20130281355A1 (en) | 2012-04-24 | 2013-10-24 | Genentech, Inc. | Cell culture compositions and methods for polypeptide production |
US8883979B2 (en) * | 2012-08-31 | 2014-11-11 | Bayer Healthcare Llc | Anti-prolactin receptor antibody formulations |
US8613919B1 (en) | 2012-08-31 | 2013-12-24 | Bayer Healthcare, Llc | High concentration antibody and protein formulations |
US9592297B2 (en) * | 2012-08-31 | 2017-03-14 | Bayer Healthcare Llc | Antibody and protein formulations |
CN105025925A (zh) * | 2013-03-15 | 2015-11-04 | 拜尔健康护理有限责任公司 | 抗-催乳素受体抗体制剂 |
KR102034757B1 (ko) | 2013-07-23 | 2019-10-21 | 바이오콘 리미티드 | Cd6 결합 파트너의 용도 및 이에 기초한 방법 |
CA3093383A1 (en) | 2014-10-24 | 2016-04-28 | Merck Sharp & Dohme Corp. | Co-agonists of the glucagon and glp-1 receptors |
JP6781508B2 (ja) * | 2014-11-18 | 2020-11-04 | 塩野義製薬株式会社 | 安定化されたペプチド組成物 |
CN104946616A (zh) * | 2015-05-12 | 2015-09-30 | 骏实生物科技(上海)有限公司 | 一种用于体外诊断试剂的通用固体稳定剂及其使用方法 |
AR104847A1 (es) * | 2015-06-17 | 2017-08-16 | Lilly Co Eli | Formulación de anticuerpo anti-cgrp |
CA2985718A1 (en) | 2015-06-24 | 2016-12-29 | F. Hoffmann-La Roche Ag | Anti-transferrin receptor antibodies with tailored affinity |
RS64263B1 (sr) * | 2015-08-19 | 2023-07-31 | Astrazeneca Ab | Stabilna anti-ifnar1 formulacija |
KR20200035496A (ko) * | 2015-09-22 | 2020-04-03 | 화이자 인코포레이티드 | 치료학적 단백질 제형의 제조 방법 및 이러한 방법에 의해 생산된 항체 제형 |
PE20231655A1 (es) | 2015-10-02 | 2023-10-17 | Hoffmann La Roche | Anticuerpos biespecificos contra el cd20 humano y el receptor de transferrina humano y metodos de uso |
AR106189A1 (es) | 2015-10-02 | 2017-12-20 | Hoffmann La Roche | ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO |
CN106620691B (zh) * | 2015-11-04 | 2020-08-21 | 信达生物制药(苏州)有限公司 | 一种重组全人源抗ctla-4单克隆抗体制剂及其应用 |
CA3007419A1 (en) | 2015-12-30 | 2017-07-06 | Genentech, Inc. | Formulations with reduced degradation of polysorbate |
CN106199007B (zh) * | 2016-08-03 | 2017-04-05 | 烟台普罗吉生物科技发展有限公司 | 蛋白保护剂 |
KR102514528B1 (ko) | 2016-10-21 | 2023-03-27 | 바이오콘 리미티드 | 루푸스 치료를 위한 단일클론항체 및 이의 치료방법 |
CN106913869B (zh) * | 2017-03-17 | 2020-07-28 | 信达生物制药(苏州)有限公司 | 一种抗ctla-4单克隆抗体制剂及其应用 |
WO2018187074A1 (en) | 2017-04-03 | 2018-10-11 | Immunomedics, Inc. | Subcutaneous administration of antibody-drug conjugates for cancer therapy |
PT3672631T (pt) * | 2017-08-22 | 2023-05-23 | Biogen Ma Inc | Composições farmacêuticas contendo anticorpos anti-betaamiloide |
CN108373494A (zh) * | 2018-02-27 | 2018-08-07 | 武汉伊艾博科技有限公司 | 一种防止重组蛋白质降解的保护技术 |
US11634485B2 (en) | 2019-02-18 | 2023-04-25 | Eli Lilly And Company | Therapeutic antibody formulation |
CN112618482A (zh) * | 2019-09-24 | 2021-04-09 | 江苏恒瑞医药股份有限公司 | 新型蛋白制剂 |
CN112741804A (zh) * | 2019-10-31 | 2021-05-04 | 上海君实生物医药科技股份有限公司 | 含有抗pd-l1抗体的稳定制剂 |
CN113116812A (zh) * | 2019-12-30 | 2021-07-16 | 百奥泰生物制药股份有限公司 | 含抗Trop2抗体-药物偶联物的制剂及其制备方法和应用 |
EP4221750A1 (en) * | 2020-09-30 | 2023-08-09 | Merck Sharp & Dohme LLC | Binding proteins and antigen binding fragments thereof that bind abeta |
CN117088974B (zh) * | 2023-08-14 | 2024-02-13 | 武汉健昊生物科技有限公司 | 一种抗体保存液 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6685940B2 (en) * | 1995-07-27 | 2004-02-03 | Genentech, Inc. | Protein formulation |
MXPA04000747A (es) * | 2001-07-25 | 2004-07-08 | Protein Desing Labs Inc | Formulacion farmaceutica liofilizada estable de anticuerpos igg. |
AR038568A1 (es) * | 2002-02-20 | 2005-01-19 | Hoffmann La Roche | Anticuerpos anti-a beta y su uso |
AU2004229335C1 (en) * | 2003-04-04 | 2010-06-17 | Genentech, Inc. | High concentration antibody and protein formulations |
GT200600031A (es) * | 2005-01-28 | 2006-08-29 | Formulacion anticuerpo anti a beta | |
SV2008002394A (es) * | 2005-01-28 | 2008-02-08 | Wyeth Corp | Formulaciones liquidas estabilizadas de polipeptido ref. ahn- 072sv |
PT1960428E (pt) * | 2005-12-12 | 2011-10-07 | Hoffmann La Roche | Anticorpos glicosilados na região variável contra beta-amilóide 4 |
WO2007110339A1 (en) * | 2006-03-28 | 2007-10-04 | F. Hoffmann-La Roche Ag | Anti-igf-1r human monoclonal antibody formulation |
-
2007
- 2007-12-11 PE PE2007001764A patent/PE20081477A1/es not_active Application Discontinuation
- 2007-12-11 CN CNA2007800455861A patent/CN101553504A/zh active Pending
- 2007-12-11 RU RU2009126420/10A patent/RU2009126420A/ru not_active Application Discontinuation
- 2007-12-11 CA CA002671968A patent/CA2671968A1/en not_active Abandoned
- 2007-12-11 BR BRPI0721097-3A patent/BRPI0721097A2/pt not_active IP Right Cessation
- 2007-12-11 EP EP07856573A patent/EP2094729A1/en not_active Withdrawn
- 2007-12-11 MX MX2009006199A patent/MX2009006199A/es not_active Application Discontinuation
- 2007-12-11 AU AU2007331712A patent/AU2007331712A1/en not_active Abandoned
- 2007-12-11 JP JP2009540650A patent/JP2010512356A/ja not_active Withdrawn
- 2007-12-11 US US12/448,190 patent/US20110070225A1/en not_active Abandoned
- 2007-12-11 AR ARP070105523A patent/AR064220A1/es unknown
- 2007-12-11 TW TW096147285A patent/TW200831133A/zh unknown
- 2007-12-11 WO PCT/EP2007/010825 patent/WO2008071394A1/en active Application Filing
- 2007-12-11 CL CL200703583A patent/CL2007003583A1/es unknown
- 2007-12-11 KR KR1020097013954A patent/KR20090104017A/ko not_active Application Discontinuation
-
2009
- 2009-05-21 CR CR10823A patent/CR10823A/es not_active Application Discontinuation
- 2009-05-26 IL IL198963A patent/IL198963A0/en unknown
- 2009-06-08 MA MA31963A patent/MA30975B1/fr unknown
- 2009-06-09 ZA ZA200904014A patent/ZA200904014B/xx unknown
- 2009-06-11 EC EC2009009403A patent/ECSP099403A/es unknown
- 2009-07-07 NO NO20092586A patent/NO20092586L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
MX2009006199A (es) | 2009-06-22 |
AU2007331712A2 (en) | 2009-07-30 |
AR064220A1 (es) | 2009-03-18 |
RU2009126420A (ru) | 2011-01-20 |
AU2007331712A1 (en) | 2008-06-19 |
CR10823A (es) | 2009-08-12 |
KR20090104017A (ko) | 2009-10-05 |
EP2094729A1 (en) | 2009-09-02 |
TW200831133A (en) | 2008-08-01 |
IL198963A0 (en) | 2011-08-01 |
JP2010512356A (ja) | 2010-04-22 |
CN101553504A (zh) | 2009-10-07 |
WO2008071394A1 (en) | 2008-06-19 |
ZA200904014B (en) | 2010-04-28 |
ECSP099403A (es) | 2009-07-31 |
CA2671968A1 (en) | 2008-06-19 |
BRPI0721097A2 (pt) | 2014-07-01 |
MA30975B1 (fr) | 2009-12-01 |
PE20081477A1 (es) | 2008-10-18 |
US20110070225A1 (en) | 2011-03-24 |
NO20092586L (no) | 2009-07-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2007003583A1 (es) | Formulacion farmaceutica estable, parenteral, del anticuerpo contra el peptido beta amiloide (abeta); y uso de la formulacion para el tratamiento de la enfermedad de alzheimer. | |
CL2004001011A1 (es) | Compuestos azabiciclicos derivados de n-arilsulfonilpiperidinas; inhibidores de la deposicion de la proteina beta amiloide; composicion farmaceutica; y su uso para el tratamiento del alzheimer y enfermedades neurodegenerativas. | |
CL2007002641A1 (es) | Compuestos derivados de pirimidinas; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de trastornos alergicos, autoinmunes, enfermedades inflamatorias. | |
CL2007001918A1 (es) | Compuestos derivados heteroarilos sustituidos; metodo para la preparacion de los compuestos; composicion farmaceutica; y uso para el tratamiento del dolor, depresion, enfermedad de alzheimer e hipertension entre otras. | |
CL2007003192A1 (es) | Compuestos derivados de arilamidas sustituidas por tiazol u oxazol; composicion farmaceutica; y uso para el tratamiento de una enfermedad del tracto urinario. | |
CL2007003262A1 (es) | Compuestos derivados de 1,4-benzotiepina-1,1-dioxido; composicion farmaceutica; y su uso para el tratamiento de trastornos del metabolismo de lipidos, hiperlipidemia, resistencia a la insulina, diabetes y trastornos del snc, entre otras enfermedades. | |
BRPI0615150A2 (pt) | agente para a profilaxia ou tratamento de diabete, sensibilizador de insulina, composto, pró-droga, agente farmacêutico, e, uso do composto ou um sal do mesmo ou uma pró-droga do mesmo | |
DOP2006000099A (es) | Anticuerpos dirigidos contra el péptido amiloide beta y métodos que utilizan los mismos | |
CL2007003797A1 (es) | Compuestos derivados de pirrolo piridina; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento de la enfermedad de alzheimer, parkinson, cancer, entre otras enfermedades. | |
BRPI0816255A2 (pt) | Produto farmacêutico, uso do produto, método para a profilaxia ou o tratamento de doenças, e, composição farmaceuticamente aceitável | |
CL2006002831A1 (es) | Compuestos derivados de sulfonamida: proceso de preparacion; composicion farmaceutica; y uso en el tratamiento de una enfermedad mediada por el receptor de glucocorticoides. | |
BRPI0806531A2 (pt) | Composto, composição farmacêutica, agente terapêutico, e, uso do composto. | |
CL2008000127A1 (es) | Compuestos derivados de n-(heteroaril)-1-heteroaril-1h-indol-2-carboxamidas; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del dolor, inflamacion, trastornos urologicos | |
CL2007003756A1 (es) | Compuestos derivados de pirazolo-quinazolina sustituidos, moduladores de la actividad de proteina quinasas; proceso de preparacion; composicion farmaceutica; y uso para el tratamiento del cancer. | |
WO2007022380A3 (en) | Bis-aryl amide compounds and methods of use | |
AR069135A1 (es) | Compuesto de alfa-(n-sulfonamido) acetamida como un inhibidor de produccion de peptido beta amiloide | |
BRPI0922435A2 (pt) | "composto de tiazolopiridina moduladores de sirtuina, composição farmacêutica compreendendo o mesmo e seu uso." | |
AR059390A1 (es) | Uso de flibanserina para el tratamiento de trastornos del deseo sexual premenopausicos | |
CL2007001724A1 (es) | Uso de un estrogeno para el tratamiento de enfermedades, condiciones o sintomas asociados con niveles deficientes de estrogenos en una mujer; composicion farmaceutica que comprende unidades de dosificacion diarias de hemidrato de estradiol > 0,75 y 1 | |
CL2008000910A1 (es) | Proteina de fusion que comprende una proteina que corta el peptido beta amiloide; composicion farmaceutica que la comprende, y su uso para prevenir y/o tratar enfermedades relacionadas con el peptido beta amiloide. | |
BRPI0814957A2 (pt) | Composto, pró-droga, agente farmacêutico, método para a profilaxia ou tratamento de uma doença, distúrbio ou condição, e, uso do composto. | |
CL2007001630A1 (es) | Compuestos derivados de pirrolidinamida; composicion farmaceutica; y uso para el tratamiento de la hepatitis c. | |
BRPI0807285A2 (pt) | "composição, método para preparar composição farmacêutica, forma unitária de dosagem, método para admnistrar um agente biologicamente ativo a um animal necessitando o agente, método para aumentar a biodisponibilidade de um agente biologicamente ativo, método para preparar uma composição e composto" | |
CL2008001960A1 (es) | Compuestos derivados de tetrahidropiranocromano, procedimiento de preparacion, composicion farmaceutica, util para inhibir gamma-secretasa, destinados al tratamiento de enfermedades neurodegenetarivas, enfermedad de alzheimer e inhibir el deposito de proteina amiloide. | |
CL2007001917A1 (es) | Compuestos derivados de azaindol espirociclicos; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento del dolor, condiciones de panico, depresion, mal de alzheimer, migrana, entre otras. |